Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626634 · ClinicalTrials.gov registry record · Phase 2
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
A Phase 2 study of Dravet Syndrome and Lennox Gastaut Syndrome, sponsored by Longboard Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 20
- Study locations
NCT05626634 is a Phase 2 study of Dravet Syndrome and Lennox Gastaut Syndrome that has completed, run by Longboard Pharmaceuticals. The registered enrollment target is 41 participants, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05626634, a Phase 2 study of Dravet Syndrome and Lennox Gastaut Syndrome, has completed, sponsored by Longboard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
Conditions Studied
Interventions
- DRUG LP352, bexicaserin
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group - Gulf Breeze
- University of Miami - Miami
- Advent Health Orlando - Orlando
- Research Institute of Orlando - Orlando
- University of South Florida - Tampa
New York
- Boston Children's Health Physicians LLP - Hawthorne
- Northwell Health - New York
- Northeast Regional Epilepsy Group - Staten Island
California
- Rancho Los Amigos National Rehabilitation Center (RLANRC) - Downey
- University of California San Francisco - San Francisco
North Carolina
- OnSite Clinical Solutions LLC - Charlotte
- Wake Forest University School of Medicine - Winston-Salem
Arkansas
- Arkansas Children's Hospital - Little Rock
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Maryland
- Mid-Atlantic Epilepsy and Sleep Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2024-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05626634
The ClinicalTrials.gov registry entry for NCT05626634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (61% lower). The listed sponsor is Longboard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention - of which LP352, bexicaserin is the first listed.
NCT05626634 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT05626634 about?
NCT05626634 is a clinical study titled "Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy". The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
What is the current status of trial NCT05626634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-11-08. Estimated completion is 2024-12-20.
What conditions does trial NCT05626634 study?
This clinical trial studies the following conditions: Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathy.
What interventions are being tested in trial NCT05626634?
The interventions under investigation include: LP352, bexicaserin (DRUG).
Who is sponsoring clinical trial NCT05626634?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626634 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
COMPLETED · Phase 2
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.